Q-omics provides the consensus-scored SNORA11B profile across patient tissues and cancer cell-line models. SNORA11B expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, SNORA11B is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, SNORA11B RNA expression shows 7,515 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight TGCT, LUAD, and LSCC as cancer lineages where SNORA11B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA11B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA11B survival associations across molecular data types. SNORA11B RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA11B RNA expression–survival associations across cancer types. High SNORA11B expression shows unfavorable associations in TGCT, READ, LIHC and PCPG, but favorable associations in CESC and BRCA. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for SNORA11B RNA expression.
This table summarizes SNORA11B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA11B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA11B shows higher tumor expression in LUAD, BRCA and COAD. The LUAD box plot shows higher SNORA11B RNA expression in tumor versus normal tissue (log2 FC = +0.780, t-test p = .005).
This table shows molecular features associated with SNORA11B in patient tissues and cancer cell lines. In patient samples, SNORA11B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
